Navigation Links
Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201,(Archexin) to Be Presented at the 43rd American Society of Clinical,Oncology Annual Meeting in Chicago

ROCKVILLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn Pharmaceuticals, Inc. (OTC BB:RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced that Dr. John Marshall, Principal Investigator of Phase I clinical trial of the Company's lead cancer compound RX-0201 (Archexin), will present results of the clinical study at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 at McCormick Place in Chicago, Illinois.

The presentation, entitled, "A Phase I Trial of RX-0201 (AKT anti-sense) in Patients with Advanced Cancer," is scheduled for Sunday, June 3, 2007 at 9am Central Time.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its unique technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. For Additional information about Rexahn visit www.rexahn.com.

Contact

Rexahn Pharmaceuticals, Inc.
Amanda Sawney, 240-268-5300 x300


'"/>




Page: 1

Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... SHANGHAI , Nov. 26, 2014  CARsgen, a ... (CAR-T) cell immunotherapy to treat a variety of cancers, ... led by BVCF, a China -based ... an immunotherapy company focused on the development of new ... collaboration with Shanghai Cancer Institute and Shanghai Renji Hospital, ...
(Date:11/26/2014)... N.C. , Nov. 25, 2014  At the ... Antonio this October, KaVo Kerr Group was ... Technology Expo, offering attendees the opportunity to see and ... well-respected key opinion leaders deliver lectures on the latest ... Group products include the new DEXIS CariVu Caries Detection ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... (OTC Bulletin Board: CGNH ) announced today that ... 2 Class B common stockholders a "Stockholder Questionnaire," which the ... count of the Company,s shares currently held in "street ... If you have not received the Stockholder Questionnaires via ...
... VILLAGE, Nev., March 8, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... rate for its 2.00% Convertible Senior Notes due February 15, 2012 ... 15, 2015 (the 2015 Notes) effective March 7, 2011, in connection ... to all stockholders who own shares of PDL on March 8, ...
Cached Medicine Technology:CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires 2PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015 2
(Date:11/28/2014)... Australia (PRWEB) November 28, 2014 ... undergone healthy growth over the past five years. ... increasing acceptance of therapies that are either alternative ... treatments. According to IBISWorld industry analyst David Whytcross, ... ageing population and growing private health insurance membership.” ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular ... Over the last decade, more than 141 serious ... using turkey fryers, according to the U.S. Consumer Product ... patient who tried to deep fry the turkey indoors, ... Dr. Arthur Sanford, a burn surgeon at Loyola University ...
(Date:11/28/2014)... 28, 2014 Not only is the ... free of petroleum, parabens and other cancer-causing agents, but ... research, education and awareness programs that help in the ... owners have raised an incredible, record-breaking contribution of $30,000 ... sales of the Sweet Red Rose Whip Moisturizer and ...
(Date:11/28/2014)... 2014 Earlier in the year, ... hugely popular, 2014 MTV Video Music Awards broadcasted ... ground-breaking celebrity centered television advertisements directed at 11.9 ... were estimated by Entertainment Weekly and ... spotlight on celebrities photographed by paparazzi smoking. In ...
(Date:11/28/2014)... November 28, 2014 A newly released ... an overview of the influenza virus that will soon be ... , The article begins with a brief explanation of ... symptoms. It reminds families that children under the age of ... from chronic diseases, such as heart and lung diseases, asthma, ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced ... composition of matter patent,protection for a series of ... R4996/MEM 63908, which are both being developed,in partnership ... such as,Alzheimer,s disease and cognitive impairment associated with ...
... people worship felines,like pharos; dog people talk to hounds ... really are different -- in marital status, economic,standing and ... that there are some interesting differences,between cat owners and ... American Veterinary Medical Association (AVMA). "Our surveys show,that single ...
... in the market for specialty needles is determined by growing demand ... is projected to reach $3.7 billion by the year 2015. ... ... The market for disposable medical products such as syringes, disposable needles, ...
... solely as disease agents -- now are being used ... these so-called oncolytic viruses stem from their potential to ... a way of controlling the viruses behind potential cancer ... microRNAs to restrict them to specific tissues. The microRNAs ...
... Consulting Service is quickly becoming the nation’s leader in ... in 2008 and has already achieved six Joint Commission certifications ... Consulting Service assures agencies understand and meet the healthcare standards ... ...
... association says cooling body, checking arteries lowers risk of further ... heart beating again is only the first step in saving ... shows. , An advisory, published in the Oct. 23 issue ... more quickly after resuscitation or risk the losing the patient ...
Cached Medicine News:Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Cat People vs. Dog People ... They Really are Different 2Health News:Special Purpose Needles Market to Reach $3.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc 2Health News:Special Purpose Needles Market to Reach $3.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc 3Health News:MicroRNAs make for safer cancer treatments 2Health News:New Joint Commission Consulting Service by NurseTesting Grows Fast as Staffing Agencies Seek Joint Commission Certification 2Health News:New Joint Commission Consulting Service by NurseTesting Grows Fast as Staffing Agencies Seek Joint Commission Certification 3Health News:Speedy Care After Heart Attack Key to Survival 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: